Veradermics, Incorporated — Company profile
Healthcare · Biotechnology · United States
Last price 139.69 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.84B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Details
| Name | Veradermics, Incorporated |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 37 |
| Founded | 2019 |
| Ipo Date | 2026-02-04 |
| Ceo | Reid Waldman |
| Country | United States |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 17.00 |
| Isin | US9229671048 |
| Cusip | 922967104 |
| Cik | 1827635 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Reid Waldman M.D. | Chief Executive Officer and Director |
| Dominic Carrano CPA | Chief Financial Officer and Treasurer |
| Dr. Timothy Durso M.D. | Chief Technical Officer |
| Michael V. Greco J.D. | General Counsel and Secretary |
| Karl Pruss | Senior Director of Manufacturing Sciences and Technology |
| Mark Neumann | Chief Commercial and Strategy Officer |
| Erika Sipperly CPA | Controller |
| Dr. Michael Smolinski Ph.D. | Vice President of Development and Scientific Operations |
| Aron Shapiro | Vice President of Clinical Development and Regulatory Affairs |
| Brian Trautman | Director of CMC Project Management |
Contact
| Address | 470 James Street, Suite 2, New Haven, Connecticut 06513, United States |
| Phone | 228 372 3376 |
| Website | https://www.veradermics.com |